{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T15:35:53Z","timestamp":1791646553445,"version":"4.3.4"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,7]],"date-time":"2020-04-07T00:00:00Z","timestamp":1586217600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,4,7]],"date-time":"2020-04-07T00:00:00Z","timestamp":1586217600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["H29-nanchitou (nan)-ippan-018"],"award-info":[{"award-number":["H29-nanchitou (nan)-ippan-018"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP17ek0109121"],"award-info":[{"award-number":["JP17ek0109121"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Relapses frequently occur in giant cell arteritis (GCA), and long-term glucocorticoid therapy is required. The identification of associated factors with poor treatment outcomes is important to decide the treatment algorithm of GCA.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We enrolled 139 newly diagnosed GCA patients treated with glucocorticoids between 2007 and 2014 in a retrospective, multi-center registry. Patients were diagnosed with temporal artery biopsy, 1990 American College of Rheumatology classification criteria, or large vessel lesions (LVLs) detected by imaging based on the modified classification criteria. Poor treatment outcomes (non-achievement of clinical remission by week 24 or relapse during 52\u2009weeks) were evaluated. Clinical remission was defined as the absence of clinical signs and symptoms in cranial and large vessel areas, polymyalgia rheumatica (PMR), and elevation of C-reactive protein (CRP) levels. A patient was determined to have a relapse if he\/she had either one of the signs and symptoms that newly appeared or worsened after achieving clinical remission. Re-elevation of CRP without clinical manifestations was considered as a relapse if other causes such as infection were excluded and the treatment was intensified. Associated factors with poor treatment outcomes were analyzed by using the Cox proportional hazard model.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Cranial lesions, PMR, and LVLs were detected in 77.7%, 41.7%, and 52.5% of the enrolled patients, respectively. Treatment outcomes were evaluated in 119 newly diagnosed patients who were observed for 24\u2009weeks or longer. The mean initial dose of prednisolone was 0.76\u2009mg\/kg\/day, and 29.4% received any concomitant immunosuppressive drugs at baseline. Overall, 41 (34.5%) of the 119 patients had poor treatment outcomes; 13 did not achieve clinical remission by week 24, and 28 had a relapse after achieving clinical remission. Cumulative rates of the events of poor treatment outcomes in patients with and without LVLs were 47.5% and 17.7%, respectively. A multivariable model showed the presence of LVLs at baseline was significantly associated with poor treatment outcomes (adjusted hazard ratio [HR] 3.54, 95% CI 1.52\u20138.24, <jats:italic>p<\/jats:italic>\u2009=\u20090.003). Cranial lesions and PMR did not increase the risk of poor treatment outcomes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The initial treatment intensity in the treatment algorithm of GCA could be determined based upon the presence or absence of LVLs detected by imaging at baseline.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13075-020-02171-6","type":"journal-article","created":{"date-parts":[[2020,4,7]],"date-time":"2020-04-07T11:03:33Z","timestamp":1586257413000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Associated factors of poor treatment outcomes in patients with giant cell arteritis: clinical implication of large vessel lesions"],"prefix":"10.1186","volume":"22","author":[{"name":"Japan Research Committee of the Ministry of Health, Labour, and Welfare for Intractable Vasculitis (JPVAS)","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiko","family":"Sugihara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruhito A.","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Yoshifuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiko","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eisuke","family":"Amiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Maejima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Konishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohko","family":"Murakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyoshi","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Furuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Katsumata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Komagata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taio","family":"Naniwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Okazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiya","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshikazu","family":"Nakaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Arimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayoshi","family":"Harigai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuaki","family":"Isobe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,7]]},"reference":[{"key":"2171_CR1","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1002\/art.11195","volume":"49","author":"S Kobayashi","year":"2003","unstructured":"Kobayashi S, Yano T, Matsumoto Y, Numano F, Nakajima N, Yasuda K, et al. Clinical and epidemiologic analysis of giant cell (temporal) arteritis from a nationwide survey in 1998 in Japan: the first government-supported nationwide survey. Arthritis Rheum. 2003;49:594\u20138.","journal-title":"Arthritis Rheum"},{"key":"2171_CR2","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1002\/1529-0131(199902)42:2<311::AID-ANR14>3.0.CO;2-F","volume":"42","author":"A Brack","year":"1999","unstructured":"Brack A, Martinez-Taboada V, Stanson A, Goronzy JJ, Weyand CM. Disease pattern in cranial and large-vessel giant cell arteritis. Arthritis Rheum. 1999;42:311\u20137.","journal-title":"Arthritis Rheum"},{"key":"2171_CR3","doi-asserted-by":"publisher","first-page":"3532","DOI":"10.1002\/art.11480","volume":"48","author":"DM Nuenninghoff","year":"2003","unstructured":"Nuenninghoff DM, Hunder GG, Christianson TJ, McClelland RL, Matteson EL. Mortality of large-artery complication (aortic aneurysm, aortic dissection, and\/or large-artery stenosis) in patients with giant cell arteritis: a population-based study over 50 years. Arthritis Rheum. 2003;48:3532\u20137.","journal-title":"Arthritis Rheum"},{"key":"2171_CR4","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1136\/annrheumdis-2012-202408","volume":"72","author":"TA Kermani","year":"2013","unstructured":"Kermani TA, Warrington KJ, Crowson CS, Ytterberg SR, Hunder GG, Gabriel SE, et al. Large-vessel involvement in giant cell arteritis: a population-based cohort study of the incidence-trends and prognosis. Ann Rheum Dis. 2013;72:1989\u201394.","journal-title":"Ann Rheum Dis"},{"key":"2171_CR5","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1136\/annrheumdis-2013-204113","volume":"74","author":"JC Robson","year":"2015","unstructured":"Robson JC, Kiran A, Maskell J, Hutchings A, Arden N, Dasgupta B, et al. The relative risk of aortic aneurysm in patients with giant cell arteritis compared with the general population of the UK. Ann Rheum Dis. 2015;74:129\u201335.","journal-title":"Ann Rheum Dis"},{"key":"2171_CR6","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.3899\/jrheum.141347","volume":"42","author":"TA Kermani","year":"2015","unstructured":"Kermani TA, Warrington KJ, Cuthbertson D, Carette S, Hoffman GS, Khalidi NA, et al. Disease relapses among patients with giant cell arteritis: a prospective, longitudinal cohort study. J Rheumatol. 2015;42:1213\u20137.","journal-title":"J Rheumatol"},{"key":"2171_CR7","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1002\/art.1780330810","volume":"33","author":"GG Hunder","year":"1990","unstructured":"Hunder GG, Bloch DA, Michel BA, Stevens MB, Arend WP, Calabrese LH, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum. 1990;33:1122\u20138.","journal-title":"Arthritis Rheum"},{"key":"2171_CR8","doi-asserted-by":"crossref","unstructured":"Dejaco C, Ramiro S, Duftner C, Besson FL, Bley TA, Blockmans D, et al. EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice. Ann Rheum Dis. 2018;77:636\u201343.","DOI":"10.1136\/annrheumdis-2017-212649"},{"key":"2171_CR9","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1136\/annrheumdis-2013-204572","volume":"73","author":"S Prieto-Gonzalez","year":"2014","unstructured":"Prieto-Gonzalez S, Depetris M, Garcia-Martinez A, Espigol-Frigole G, Tavera-Bahillo I, Corbera-Bellata M, et al. Positron emission tomography assessment of large vessel inflammation in patients with newly diagnosed, biopsy-proven giant cell arteritis: a prospective, case-control study. Ann Rheum Dis. 2014;73:1388\u201392.","journal-title":"Ann Rheum Dis"},{"key":"2171_CR10","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1136\/ard.2008.088351","volume":"68","author":"C Mukhtyar","year":"2009","unstructured":"Mukhtyar C, Guillevin L, Cid MC, Dasgupta B, de Groot K, Gross W, et al. EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 2009;68:318\u201323.","journal-title":"Ann Rheum Dis"},{"key":"2171_CR11","doi-asserted-by":"crossref","unstructured":"Hellmich B, Agueda A, Monti S, Buttgereit F, de Boysson H, Brouwer E, et al. 2018 update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 2020;79:19\u201330.","DOI":"10.1136\/annrheumdis-2019-215672"},{"key":"2171_CR12","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1002\/art.11388","volume":"49","author":"A Proven","year":"2003","unstructured":"Proven A, Gabriel SE, Orces C, O\u2019Fallon WM, Hunder GG. Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. Arthritis Rheum. 2003;49:703\u20138.","journal-title":"Arthritis Rheum"},{"key":"2171_CR13","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1093\/rheumatology\/kev348","volume":"55","author":"C Labarca","year":"2016","unstructured":"Labarca C, Koster MJ, Crowson CS, Makol A, Ytterberg SR, Matteson EL, et al. Predictors of relapse and treatment outcomes in biopsy-proven giant cell arteritis: a retrospective cohort study. Rheumatology (Oxford). 2016;55:347\u201356.","journal-title":"Rheumatology (Oxford)"},{"key":"2171_CR14","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.semarthrit.2016.11.006","volume":"46","author":"JC Wilson","year":"2017","unstructured":"Wilson JC, Sarsour K, Collinson N, Tuckwell K, Musselman D, Klearman M, et al. Serious adverse effects associated with glucocorticoid therapy in patients with giant cell arteritis (GCA): a nested case-control analysis. Semin Arthritis Rheum. 2017;46:819\u201327.","journal-title":"Semin Arthritis Rheum"},{"key":"2171_CR15","doi-asserted-by":"publisher","first-page":"ii1","DOI":"10.1093\/rheumatology\/key003","volume":"57","author":"JH Stone","year":"2018","unstructured":"Stone JH. Foreword: clinical challenges of diagnosing and managing giant cell arteritis. Rheumatology (Oxford). 2018;57:ii1\u20132.","journal-title":"Rheumatology (Oxford)"},{"key":"2171_CR16","doi-asserted-by":"publisher","first-page":"621","DOI":"10.7326\/0003-4819-146-9-200705010-00004","volume":"146","author":"GS Hoffman","year":"2007","unstructured":"Hoffman GS, Cid MC, Rendt-Zagar KE, Merkel PA, Weyand CM, Stone JH, et al. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med. 2007;146:621\u201330.","journal-title":"Ann Intern Med"},{"key":"2171_CR17","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1136\/annrheumdis-2013-203586","volume":"73","author":"R Seror","year":"2014","unstructured":"Seror R, Baron G, Hachulla E, Debandt M, Larroche C, Puechal X, et al. Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomised controlled trial. Ann Rheum Dis. 2014;73:2074\u201381.","journal-title":"Ann Rheum Dis"},{"key":"2171_CR18","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1613849","volume":"377","author":"JH Stone","year":"2017","unstructured":"Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, et al. Trial of tocilizumab in giant-cell arteritis. N Engl J Med. 2017;377:317\u201328.","journal-title":"N Engl J Med"},{"key":"2171_CR19","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.semarthrit.2016.11.002","volume":"46","author":"K Tuckwell","year":"2017","unstructured":"Tuckwell K, Collinson N, Dimonaco S, Klearman M, Blockmans D, Brouwer E, et al. Newly diagnosed vs. relapsing giant cell arteritis: baseline data from the GiACTA trial. Semin Arthritis Rheum. 2017;46:657\u201364.","journal-title":"Semin Arthritis Rheum"},{"key":"2171_CR20","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1093\/rheumatology\/keu329","volume":"54","author":"F Muratore","year":"2015","unstructured":"Muratore F, Kermani TA, Crowson CS, Green AB, Salvarani C, Matteson EL, et al. Large-vessel giant cell arteritis: a cohort study. Rheumatology (Oxford). 2015;54:463\u201370.","journal-title":"Rheumatology (Oxford)"},{"key":"2171_CR21","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.autrev.2017.11.029","volume":"17","author":"H de Boysson","year":"2018","unstructured":"de Boysson H, Daumas A, Vautier M, Parienti JJ, Liozon E, Lambert M, et al. Large-vessel involvement and aortic dilation in giant-cell arteritis. A multicenter study of 549 patients. Autoimmun Rev. 2018;17:391\u20138.","journal-title":"Autoimmun Rev"},{"key":"2171_CR22","doi-asserted-by":"publisher","first-page":"e3851","DOI":"10.1097\/MD.0000000000003851","volume":"95","author":"H de Boysson","year":"2016","unstructured":"de Boysson H, Liozon E, Lambert M, Parienti JJ, Artigues N, Geffray L, et al. 18F-fluorodeoxyglucose positron emission tomography and the risk of subsequent aortic complications in giant-cell arteritis: a multicenter cohort of 130 patients. Medicine (Baltimore). 2016;95:e3851.","journal-title":"Medicine (Baltimore)"},{"key":"2171_CR23","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1136\/annrheumdis-2011-200865","volume":"71","author":"S Prieto-Gonzalez","year":"2012","unstructured":"Prieto-Gonzalez S, Arguis P, Garcia-Martinez A, Espigol-Frigole G, Tavera-Bahillo I, Butjosa M, et al. Large vessel involvement in biopsy-proven giant cell arteritis: prospective study in 40 newly diagnosed patients using CT angiography. Ann Rheum Dis. 2012;71:1170\u20136.","journal-title":"Ann Rheum Dis"},{"key":"2171_CR24","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1097\/01.md.0000145366.40805.f8","volume":"83","author":"MA Gonzalez-Gay","year":"2004","unstructured":"Gonzalez-Gay MA, Garcia-Porrua C, Pineiro A, Pego-Reigosa R, Llorca J, Hunder GG. Aortic aneurysm and dissection in patients with biopsy-proven giant cell arteritis from northwestern Spain: a population-based study. Medicine (Baltimore). 2004;83:335\u201341.","journal-title":"Medicine (Baltimore)"},{"key":"2171_CR25","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1002\/art.23315","volume":"59","author":"A Garcia-Martinez","year":"2008","unstructured":"Garcia-Martinez A, Hernandez-Rodriguez J, Arguis P, Paredes P, Segarra M, Lozano E, et al. Development of aortic aneurysm\/dilatation during the followup of patients with giant cell arteritis: a cross-sectional screening of fifty-four prospectively followed patients. Arthritis Rheum. 2008;59:422\u201330.","journal-title":"Arthritis Rheum"},{"key":"2171_CR26","doi-asserted-by":"publisher","first-page":"912562","DOI":"10.1155\/2013\/912562","volume":"2013","author":"SH Unizony","year":"2013","unstructured":"Unizony SH, Dasgupta B, Fisheleva E, Rowell L, Schett G, Spiera R, et al. Design of the tocilizumab in giant cell arteritis trial. Int J Rheumatol. 2013;2013:912562.","journal-title":"Int J Rheumatol"},{"key":"2171_CR27","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1136\/annrheumdis-2011-200795","volume":"71","author":"PC Grayson","year":"2012","unstructured":"Grayson PC, Maksimowicz-McKinnon K, Clark TM, Tomasson G, Cuthbertson D, Carette S, et al. Distribution of arterial lesions in Takayasu\u2019s arteritis and giant cell arteritis. Ann Rheum Dis. 2012;71:1329\u201334.","journal-title":"Ann Rheum Dis"},{"key":"2171_CR28","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/art.1780371020","volume":"37","author":"JM Evans","year":"1994","unstructured":"Evans JM, Bowles CA, Bjornsson J, Mullany CJ, Hunder GG. Thoracic aortic aneurysm and rupture in giant cell arteritis. A descriptive study of 41 cases. Arthritis Rheum. 1994;37:1539\u201347.","journal-title":"Arthritis Rheum"},{"key":"2171_CR29","doi-asserted-by":"publisher","first-page":"3522","DOI":"10.1002\/art.11353","volume":"48","author":"DM Nuenninghoff","year":"2003","unstructured":"Nuenninghoff DM, Hunder GG, Christianson TJ, McClelland RL, Matteson EL. Incidence and predictors of large-artery complication (aortic aneurysm, aortic dissection, and\/or large-artery stenosis) in patients with giant cell arteritis: a population-based study over 50 years. Arthritis Rheum. 2003;48:3522\u201331.","journal-title":"Arthritis Rheum"},{"key":"2171_CR30","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1097\/RHU.0000000000000381","volume":"22","author":"TA Kermani","year":"2016","unstructured":"Kermani TA, Warrington KJ, Crowson CS, Hunder GG, Ytterberg SR, Gabriel SE, et al. Predictors of dissection in aortic aneurysms from giant cell arteritis. J Clin Rheumatol. 2016;22:184\u20137.","journal-title":"J Clin Rheumatol"},{"key":"2171_CR31","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.3899\/jrheum.161467","volume":"44","author":"AG Sreih","year":"2017","unstructured":"Sreih AG, Alibaz-Oner F, Kermani TA, Aydin SZ, Cronholm PF, Davis T, et al. Development of a core set of outcome measures for large-vessel vasculitis: report from OMERACT 2016. J Rheumatol. 2017;44:1933\u20137.","journal-title":"J Rheumatol"},{"key":"2171_CR32","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.3899\/jrheum.141144","volume":"42","author":"SZ Aydin","year":"2015","unstructured":"Aydin SZ, Direskeneli H, Sreih A, Alibaz-Oner F, Gul A, Kamali S, et al. Update on outcome measure development for large vessel vasculitis: report from OMERACT 12. J Rheumatol. 2015;42:2465\u20139.","journal-title":"J Rheumatol"},{"key":"2171_CR33","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.3899\/jrheum.151063","volume":"43","author":"TA Kermani","year":"2016","unstructured":"Kermani TA, Cuthbertson D, Carette S, Hoffman GS, Khalidi NA, Koening CL, et al. The Birmingham Vasculitis Activity Score as a measure of disease activity in patients with giant cell arteritis. J Rheumatol. 2016;43:1078\u201384.","journal-title":"J Rheumatol"},{"key":"2171_CR34","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1093\/rheumatology\/kex397","volume":"57","author":"TA Kermani","year":"2018","unstructured":"Kermani TA, Sreih AG, Cuthbertson D, Carette S, Hoffman GS, Khalidi NA, et al. Evaluation of damage in giant cell arteritis. Rheumatology (Oxford). 2018;57:322\u20138.","journal-title":"Rheumatology (Oxford)"},{"key":"2171_CR35","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/j.amjmed.2017.03.054","volume":"130","author":"H de Boysson","year":"2017","unstructured":"de Boysson H, Liozon E, Lambert M, Dumont A, Boutemy J, Maigne G, et al. Giant-cell arteritis: do we treat patients with large-vessel involvement differently? Am J Med. 2017;130:992\u20135.","journal-title":"Am J Med"},{"key":"2171_CR36","doi-asserted-by":"crossref","unstructured":"Garcia-Martinez A, Arguis P, Prieto-Gonzalez S, Espigol-Frigole G, Alba MA, Butjosa M, et al. Prospective long term follow-up of a cohort of patients with giant cell arteritis screened for aortic structural damage (aneurysm or dilatation). Ann Rheum Dis. 2014;73:1826\u201332.","DOI":"10.1136\/annrheumdis-2013-203322"},{"key":"2171_CR37","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1016\/j.jvs.2014.12.045","volume":"61","author":"M Czihal","year":"2015","unstructured":"Czihal M, Piller A, Schroettle A, Kuhlencordt P, Bernau C, Schulze-Koops H, et al. Impact of cranial and axillary\/subclavian artery involvement by color duplex sonography on response to treatment in giant cell arteritis. J Vasc Surg. 2015;61:1285\u201391.","journal-title":"J Vasc Surg"},{"key":"2171_CR38","doi-asserted-by":"publisher","first-page":"e3818","DOI":"10.1097\/MD.0000000000003818","volume":"95","author":"H de Boysson","year":"2016","unstructured":"de Boysson H, Lambert M, Liozon E, Boutemy J, Maigne G, Ollivier Y, et al. Giant-cell arteritis without cranial manifestations: working diagnosis of a distinct disease pattern. Medicine (Baltimore). 2016;95:e3818.","journal-title":"Medicine (Baltimore)"},{"key":"2171_CR39","doi-asserted-by":"publisher","first-page":"e3210","DOI":"10.1097\/MD.0000000000003210","volume":"95","author":"A Hocevar","year":"2016","unstructured":"Hocevar A, Rotar Z, Jese R, Semrl SS, Pizem J, Hawlina M, et al. Do early diagnosis and glucocorticoid treatment decrease the risk of permanent visual loss and early relapses in giant cell arteritis: a prospective longitudinal study. Medicine (Baltimore). 2016;95:e3210.","journal-title":"Medicine (Baltimore)"},{"key":"2171_CR40","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1093\/rheumatology\/ken465","volume":"48","author":"C Salvarani","year":"2009","unstructured":"Salvarani C, Della Bella C, Cimino L, Macchioni P, Formisano D, Bajocchi G, et al. Risk factors for severe cranial ischaemic events in an Italian population-based cohort of patients with giant cell arteritis. Rheumatology (Oxford). 2009;48:250\u20133.","journal-title":"Rheumatology (Oxford)"},{"key":"2171_CR41","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/art.21075","volume":"53","author":"C Salvarani","year":"2005","unstructured":"Salvarani C, Cimino L, Macchioni P, Consonni D, Cantini F, Bajocchi G, et al. Risk factors for visual loss in an Italian population-based cohort of patients with giant cell arteritis. Arthritis Rheum. 2005;53:293\u20137.","journal-title":"Arthritis Rheum"},{"key":"2171_CR42","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1002\/art.40876","volume":"71","author":"JH Stone","year":"2019","unstructured":"Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, et al. Glucocorticoid dosages and acute-phase reactant levels at giant cell arteritis flare in a randomized trial of tocilizumab. Arthritis Rheumatol. 2019;71:1329\u201338.","journal-title":"Arthritis Rheumatol"},{"key":"2171_CR43","doi-asserted-by":"publisher","first-page":"e486","DOI":"10.1097\/MD.0000000000000486","volume":"94","author":"S Prieto-Gonzalez","year":"2015","unstructured":"Prieto-Gonzalez S, Garcia-Martinez A, Tavera-Bahillo I, Hernandez-Rodriguez J, Gutierrez-Chacoff J, Alba MA, et al. Effect of glucocorticoid treatment on computed tomography angiography detected large-vessel inflammation in giant-cell arteritis. A prospective, longitudinal study. Medicine (Baltimore). 2015;94:e486.","journal-title":"Medicine (Baltimore)"},{"key":"2171_CR44","doi-asserted-by":"crossref","unstructured":"Muratore F, Kermani TA, Crowson CS, Koster MJ, Matteson EL, Salvarani C, et al. Large vessel dilatation in giant cell arteritis: a different subset of disease? Arthritis Care Res (Hoboken). 2017;70:1406\u201311.","DOI":"10.1002\/acr.23498"},{"key":"2171_CR45","doi-asserted-by":"crossref","unstructured":"Kermani TA, Diab S, Sreih AG, Cuthbertson D, Borchin R, Carette S, et al. Arterial lesions in giant cell arteritis: a longitudinal study. Semin Arthritis Rheum. 2019;48:707\u201313.","DOI":"10.1016\/j.semarthrit.2018.05.002"},{"key":"2171_CR46","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.3899\/jrheum.120511","volume":"39","author":"O Espitia","year":"2012","unstructured":"Espitia O, Neel A, Leux C, Connault J, Espitia-Thibault A, Ponge T, et al. Giant cell arteritis with or without aortitis at diagnosis. A retrospective study of 22 patients with longterm followup. J Rheumatol. 2012;39:2157\u201362.","journal-title":"J Rheumatol"},{"key":"2171_CR47","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1002\/art.40379","volume":"70","author":"PC Grayson","year":"2018","unstructured":"Grayson PC, Alehashemi S, Bagheri AA, Civelek AC, Cupps TR, Kaplan MJ, et al. (18) F-fluorodeoxyglucose-positron emission tomography as an imaging biomarker in a prospective, longitudinal cohort of patients with large vessel vasculitis. Arthritis Rheumatol. 2018;70:439\u201349.","journal-title":"Arthritis Rheumatol."},{"key":"2171_CR48","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1136\/annrheumdis-2018-213102","volume":"77","author":"KA Quinn","year":"2018","unstructured":"Quinn KA, Ahlman MA, Malayeri AA, Marko J, Civelek AC, Rosenblum JS, et al. Comparison of magnetic resonance angiography and (18)F-fluorodeoxyglucose positron emission tomography in large-vessel vasculitis. Ann Rheum Dis. 2018;77:1165\u201371.","journal-title":"Ann Rheum Dis"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-020-02171-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13075-020-02171-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-020-02171-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,6]],"date-time":"2021-04-06T23:43:52Z","timestamp":1617752632000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-020-02171-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,7]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2171"],"URL":"https:\/\/doi.org\/10.1186\/s13075-020-02171-6","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,7]]},"assertion":[{"value":"25 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and the Ethical Guidelines for Epidemiological Research in Japan. The institutional review board of Tokyo Medical and Dental University as the main center (approval number: M2000-2084-01) and the additional 23 institutions approved our retrospective study without personally identifiable information. Patients received posters informing the present study, or the posters were displayed in the outpatient clinic of each facility.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"TS has received research grants and\/or honoraria from Abbvie Japan Co., Ltd., AsahiKASEI Co., Ltd.; Astellas Pharma Inc.; Ayumi Pharmaceutical; Bristol Myers Squibb K.K.; Chugai Pharmaceutical Co., Ltd.; Daiichi Sankyo; Eli Lilly Japan K.K.; Mitsubishi-Tanabe Pharma Co.; Ono Pharmaceutical; Pfizer Japan, Inc.; Takeda Pharmaceutical Co., Ltd.; and UCB Japan Co., Ltd. Tokyo Medical and Dental University received unrestricted research grants from Department of Lifetime Clinical Immunology from Ayumi Pharmaceutical Corporation; Chugai Pharmaceutical Co., Ltd.; CSL Behring K.K.; Japan Blood Products Organization; and UCB Japan Co., Ltd. HH has received honoraria from Chugai Pharmaceutical Co., Ltd.; Takeda Pharmaceutical Co., Ltd.; Mitsubishi-Tanabe Pharma Co.; Astellas Pharma Inc.; Bristol Myers Squibb K.K.; Pfizer Japan Inc.; Eli Lilly Japan K.K.; AsahiKASEI Co., Ltd.; Teijin Pharma Ltd.; and Abbvie Japan Co., Ltd. HAU belongs to the Department of Chronic Kidney Disease and Cardiovascular Disease which is endowed by Chugai Pharmaceutical, MSD, Boehringer Ingelheim, and Kawanishi Holdings. HY has received lecture fees from Chugai Pharmaceutical Co., Ltd. and Nihon Medi-Physics Co., Ltd. YW have received honoraria from Chugai Pharmaceutical Co., Ltd. EA belongs to the Department of Therapeutic Strategy for Heart Failure, Graduate School of Medicine, University of Tokyo, which is endowed by Actelion Pharmaceuticals Japan Ltd., Otsuka Pharmaceutical, NIPRO CORPORATION, Terumo Corp., Senko Medical Instrument Mfg., Century Medical Inc., Kinetic Concepts Inc., and St. Jude Medical. EA has received honoraria from Takeda Pharmaceutical Co. Ltd., Bayer Yakuhin. Ltd., Otsuka Pharmaceutical Co., Ltd. YM has received honoraria from Chugai Pharmaceutical Co., Ltd. MK has nothing to declare. YM has received honoraria from Abbvie, Astellas, Ayumi Pharmaceutical, Bristol Myers Squibb, Chugai Pharmaceutical, Eisai Pharmaceutical, Janssen Pharmaceutical, Kissei Pharmaceutical, Nippon Kayaku, Pfizer Pharmaceutical, Takeda Pharmaceutical, and UCB Pharmaceutical and has received research grant support from Asahi Kasei Pharma, Chugai Pharmaceutical, Daiichi Sankyo, Eisai Pharmaceutical, Mitsubishi Tanabe Pharma, Nippon Kayaku, Ono Pharmaceutical, Gilead Sciences Inc., Janssen Pharmaceutical, and Teijin Pharma. NO and SF have nothing to declare. YK has received honoraria from Chugai Pharmaceutical Co., Ltd.; Glaxo-Smithkline K.K.; Sanofi K.K.; Pfizer Japan Inc.; and Asahi Kasei Pharma Corp. YK has received consulting fees from Chugai, Kyowa Hakko Kirin, Asahi Kasei, and UCB and speakers\u2019 fees from Bristol-Myers Squibb, Eli Lilly, Janssen, Novartis, Daiichi Sankyo, AbbVie, Nippon Shinyaku, and Towa. TN has received research grants and lecture fees from Chugai Pharmaceutical Co., Ltd. TO has received research grants from Chugai Pharmaceutical Co., Ltd.; Eisai Pharmaceutical.; and Actelion. YT has received consulting fees, speaking fees, and\/or honoraria from Daiichi-Sankyo, Astellas, Pfizer, Mitsubishi-Tanabe, Bristol-Myers, Chugai, YL Biologics, Eli Lilly, Sanofi, Janssen, and UCB and has received research grants from Mitsubishi-Tanabe, Takeda, Bristol-Myers, Chugai, Astellas, Abbvie, MSD, Daiichi-Sankyo, Pfizer, Kyowa-Kirin, Eisai, and Ono. TT has received research grants from Astellas, Chugai, Daiichi Sankyo, Takeda, AbbVie, Asahi Kasei, Mitsubishi Tanabe, Pfizer, Eisai, AYUMI, Nippon Kayaku, and Novartis; has received consulting fees from Astra Zeneca, Eli Lilly, Novartis, Mitsubishi Tanabe, AbbVie, Nippon Kayaku, Janssen, Astellas, Taiho, Chugai, Taisho Toyama, GlaxoSmithKline, and UCB; and has served on speakers\u2019 fees for AbbVie, Bristol-Myers Squibb, Chugai, Mitsubishi Tanabe, Pfizer, Astellas, Daiichi Sankyo, Eisai, Sanofi, Teijin, Takeda, and Novartis. YN has received research grants from Bayer Yakuhin, Ltd.; has received consulting fees and\/or lecture fees and\/or research grants from Chugai; has received consulting fees and\/or lecture fees from AbbVie; and has received lecture fees from Astellas, Pfizer, MSD, Daiichi Sankyo, and Kowa. YA has received honoraria from Mitsubishi Tanabe Pharma Co.; Nippon Shinyaku Co., Ltd.; Chugai Pharmaceutical Co., Ltd.; Teijin Pharma, Ltd.; Asahi Kasei Corporation; AbbVie GK; F. Hoffmann-La Roche, Ltd.; GlaxoSmithKline K.K.; KYORIN Pharmaceutical Co., Ltd.; Kyowa Hakko Kirin Company, Ltd.; and Astellas Pharma Inc. MH has received research grants and\/or honoraria from Abbott Japan Co., Ltd.; Astellas Pharma Inc.; Bristol-Myers Squibb K.K.; Chugai Pharmaceutical Co., Ltd.; Eisai Co., Ltd.; Janssen Pharmaceutical K.K.; Mitsubishi Tanabe Pharma Co.; Santen Pharmaceutical Co., Ltd.; Takeda Pharmaceutical Co., Ltd.; Teijin Pharma, Ltd.; and Pfizer Japan Inc. MI has received research grants and\/or honoraria from Chugai, Ono, Otsuka, Teijin, Mitsubishi-Tanabe, and Daiichi Sankyo.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"72"}}